Blair William & Co. IL Sells 13,724 Shares of Insulet Corporation $PODD

Key Points

• Blair William & Co. IL reduced its stake in Insulet Corporation by 7.7%, selling 13,724 shares in the second quarter, leaving them with 163,555 shares valued at approximately $51.4 million.
• Insulet reported strong earnings in Q2, with an EPS of $1.17, surpassing analysts' expectations of $0.92, and a revenue increase of 32.9% year-on-year.
• Several hedge funds have recently adjusted their positions in Insulet, including Larson Financial Group, which raised its stake by 426.3% in Q1.

Blair William & Co. IL decreased its stake in Insulet Corporation (NASDAQ:PODD - Free Report) by 7.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 163,555 shares of the medical instruments supplier's stock after selling 13,724 shares during the period. Blair William & Co. IL owned about 0.23% of Insulet worth $51,386,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Zions Bancorporation National Association UT acquired a new stake in shares of Insulet during the 1st quarter valued at $26,000. Larson Financial Group LLC raised its position in Insulet by 426.3% in the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock valued at $26,000 after purchasing an additional 81 shares during the last quarter. SouthState Corp raised its position in Insulet by 253.3% in the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock valued at $28,000 after purchasing an additional 76 shares during the last quarter. Kozak & Associates Inc. acquired a new stake in shares of Insulet during the second quarter valued at about $32,000. Finally, Ramirez Asset Management Inc. bought a new stake in shares of Insulet during the first quarter worth about $53,000.

Insider Activity

In other Insulet news, SVP Laetitia Cousin sold 797 shares of the firm's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the sale, the senior vice president owned 3,890 shares of the company's stock, valued at approximately $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Prem Singh sold 687 shares of the business's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president owned 3,456 shares of the company's stock, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.39% of the company's stock.

Insulet Price Performance

Insulet stock opened at $320.38 on Friday. The stock has a market capitalization of $22.55 billion, a price-to-earnings ratio of 97.38, a PEG ratio of 2.62 and a beta of 1.40. Insulet Corporation has a 52-week low of $226.50 and a 52-week high of $353.50. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. The stock's 50 day moving average price is $323.15 and its two-hundred day moving average price is $299.83.

Insulet (NASDAQ:PODD - Get Free Report) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.92 by $0.25. The company had revenue of $649.10 million for the quarter, compared to the consensus estimate of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. Insulet's quarterly revenue was up 32.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities analysts predict that Insulet Corporation will post 3.92 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Truist Financial began coverage on shares of Insulet in a report on Monday, June 16th. They issued a "buy" rating and a $365.00 price objective for the company. Wells Fargo & Company upped their price target on shares of Insulet from $330.00 to $350.00 and gave the company an "overweight" rating in a research report on Friday, August 8th. Royal Bank Of Canada lifted their price target on shares of Insulet from $330.00 to $350.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Weiss Ratings reissued a "hold (c)" rating on shares of Insulet in a research note on Wednesday. Finally, Canaccord Genuity Group raised their target price on Insulet from $353.00 to $399.00 and gave the stock a "buy" rating in a research report on Monday, September 29th. Seventeen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $346.83.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.